← Back to Search

Monoclonal Antibodies

Expansion Adults: MT-0169 for Leukemia

Phase 1
Waitlist Available
Led By Abhishek Maiti, MBBS
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. Patients need to be ≥ 12 years of age.
2. ECOG performance status of o to 2.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; an average of 1 year.
Awards & highlights

Summary

To learn if MT-0169 is safe to give to patients with AML or T-ALL. The effects of this drug will also be studied.

Who is the study for?
This trial is for patients with acute leukemia (AML or T-ALL) who have either not responded to previous treatments (relapsed/refractory) or still show signs of disease. Specific details on eligibility criteria are not provided.
What is being tested?
The safety and effects of a new drug called MT-0169 are being tested in this Phase I trial for individuals with CD38+ acute leukemia, specifically AML or T-ALL.
What are the potential side effects?
Potential side effects of MT-0169 are not listed, but common ones may include reactions at the injection site, fatigue, fever, nausea, and blood count changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; an average of 1 year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average of 1 year. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Trial Design

4Treatment groups
Experimental Treatment
Group I: Expansion Pediatrics: MT-0169Experimental Treatment1 Intervention
Group II: Expansion Adults: MT-0169Experimental Treatment1 Intervention
Group III: Escalation Pediatrics: MT-0169Experimental Treatment1 Intervention
Group IV: Escalation Adults: MT-0169Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,030 Previous Clinical Trials
1,797,195 Total Patients Enrolled
460 Trials studying Leukemia
31,772 Patients Enrolled for Leukemia
Abhishek Maiti, MBBSPrincipal InvestigatorM.D. Anderson Cancer Center
3 Previous Clinical Trials
267 Total Patients Enrolled
3 Trials studying Leukemia
267 Patients Enrolled for Leukemia
~35 spots leftby Jul 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top